Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 280

1.

Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent.

Wang P, Li X, Wang J, Gao D, Li Y, Li H, Chu Y, Zhang Z, Liu H, Jiang G, Cheng Z, Wang S, Dong J, Feng B, Chard LS, Lemoine NR, Wang Y.

Nat Commun. 2018 Jan 10;9(1):203. doi: 10.1038/s41467-017-02205-9.

2.

Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent.

Wang P, Li X, Wang J, Gao D, Li Y, Li H, Chu Y, Zhang Z, Liu H, Jiang G, Cheng Z, Wang S, Dong J, Feng B, Chard LS, Lemoine NR, Wang Y.

Nat Commun. 2017 Nov 9;8(1):1395. doi: 10.1038/s41467-017-01385-8. Erratum in: Nat Commun. 2018 Jan 10;9(1):203.

3.

The Pancreatic Expression Database: 2018 update.

Marzec J, Dayem Ullah AZ, Pirrò S, Gadaleta E, Crnogorac-Jurcevic T, Lemoine NR, Kocher HM, Chelala C.

Nucleic Acids Res. 2018 Jan 4;46(D1):D1107-D1110. doi: 10.1093/nar/gkx955.

4.

'Multi-omic' data analysis using O-miner.

Sangaralingam A, Dayem Ullah AZ, Marzec J, Gadaleta E, Nagano A, Ross-Adams H, Wang J, Lemoine NR, Chelala C.

Brief Bioinform. 2017 Aug 4. doi: 10.1093/bib/bbx080. [Epub ahead of print]

PMID:
28981577
5.

Correction for Spurrell et al., "STAT1 Interaction with E3-14.7K in Monocytes Affects the Efficacy of Oncolytic Adenovirus".

Spurrell E, Gangeswaran R, Wang P, Cao F, Gao D, Feng B, Wold W, Tollefson A, Lemoine NR, Wang Y.

J Virol. 2017 Sep 27;91(20). pii: e00670-17. doi: 10.1128/JVI.00670-17. Print 2017 Oct 15. No abstract available.

6.

Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer.

Howells A, Marelli G, Lemoine NR, Wang Y.

Front Oncol. 2017 Sep 8;7:195. doi: 10.3389/fonc.2017.00195. eCollection 2017. Review.

7.

Immune checkpoint inhibitors in cancer therapy.

Webb ES, Liu P, Baleeiro R, Lemoine NR, Yuan M, Wang YH.

J Biomed Res. 2017 Sep 3. doi: 10.7555/JBR.31.20160168. [Epub ahead of print]

8.

Splice variants as novel targets in pancreatic ductal adenocarcinoma.

Wang J, Dumartin L, Mafficini A, Ulug P, Sangaralingam A, Alamiry NA, Radon TP, Salvia R, Lawlor RT, Lemoine NR, Scarpa A, Chelala C, Crnogorac-Jurcevic T.

Sci Rep. 2017 Jun 7;7(1):2980. doi: 10.1038/s41598-017-03354-z.

9.

ER stress protein AGR2 precedes and is involved in the regulation of pancreatic cancer initiation.

Dumartin L, Alrawashdeh W, Trabulo SM, Radon TP, Steiger K, Feakins RM, di Magliano MP, Heeschen C, Esposito I, Lemoine NR, Crnogorac-Jurcevic T.

Oncogene. 2017 Jun 1;36(22):3094-3103. doi: 10.1038/onc.2016.459. Epub 2016 Dec 12.

10.

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors.

Yuan M, Wang P, Chard LS, Lemoine NR, Wang Y.

J Vis Exp. 2016 Oct 30;(116). doi: 10.3791/54171.

PMID:
27842362
11.

Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma.

Carapuça EF, Gemenetzidis E, Feig C, Bapiro TE, Williams MD, Wilson AS, Delvecchio FR, Arumugam P, Grose RP, Lemoine NR, Richards FM, Kocher HM.

J Pathol. 2016 Jul;239(3):286-96. doi: 10.1002/path.4727. Epub 2016 May 25.

12.

CRISPR-Cas9 as a Powerful Tool for Efficient Creation of Oncolytic Viruses.

Yuan M, Webb E, Lemoine NR, Wang Y.

Viruses. 2016 Mar 7;8(3):72. doi: 10.3390/v8030072. Review.

13.

The E1B19K-deleted oncolytic adenovirus mutant AdΔ19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11.

Pantelidou C, Cherubini G, Lemoine NR, Halldén G.

Oncotarget. 2016 Mar 29;7(13):15703-24. doi: 10.18632/oncotarget.7310.

14.

Vaccinia virus, a promising new therapeutic agent for pancreatic cancer.

Al Yaghchi C, Zhang Z, Alusi G, Lemoine NR, Wang Y.

Immunotherapy. 2015;7(12):1249-58. doi: 10.2217/imt.15.90. Epub 2015 Nov 23. Review.

15.

Immune-checkpoint blockade: the springboard for immuno-combination therapy.

Ibrahim AM, Wang Y, Lemoine NR.

Gene Ther. 2015 Nov;22(11):849-50. doi: 10.1038/gt.2015.98. No abstract available.

PMID:
26537748
16.

A marker-free system for highly efficient construction of vaccinia virus vectors using CRISPR Cas9.

Yuan M, Gao X, Chard LS, Ali Z, Ahmed J, Li Y, Liu P, Lemoine NR, Wang Y.

Mol Ther Methods Clin Dev. 2015 Sep 16;2:15035. doi: 10.1038/mtm.2015.35. eCollection 2015.

17.

New role of Interleukin-10 in enhancing the antitumor efficacy of oncolytic vaccinia virus for treatment of pancreatic cancer.

Chard LS, Lemoine NR, Wang Y.

Oncoimmunology. 2015 Jul 20;4(9):e1038689. eCollection 2015 Sep.

18.

Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma.

Radon TP, Massat NJ, Jones R, Alrawashdeh W, Dumartin L, Ennis D, Duffy SW, Kocher HM, Pereira SP, Guarner posthumous L, Murta-Nascimento C, Real FX, Malats N, Neoptolemos J, Costello E, Greenhalf W, Lemoine NR, Crnogorac-Jurcevic T.

Clin Cancer Res. 2015 Aug 1;21(15):3512-21. doi: 10.1158/1078-0432.CCR-14-2467.

19.

Lister strain vaccinia virus with thymidine kinase gene deletion is a tractable platform for development of a new generation of oncolytic virus.

Hughes J, Wang P, Alusi G, Shi H, Chu Y, Wang J, Bhakta V, McNeish I, McCart A, Lemoine NR, Wang Y.

Gene Ther. 2015 Jun;22(6):476-84. doi: 10.1038/gt.2015.13. Epub 2015 Apr 16.

PMID:
25876464
20.

Efficiently editing the vaccinia virus genome by using the CRISPR-Cas9 system.

Yuan M, Zhang W, Wang J, Al Yaghchi C, Ahmed J, Chard L, Lemoine NR, Wang Y.

J Virol. 2015 May;89(9):5176-9. doi: 10.1128/JVI.00339-15. Epub 2015 Mar 4.

21.

A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma.

Haider S, Wang J, Nagano A, Desai A, Arumugam P, Dumartin L, Fitzgibbon J, Hagemann T, Marshall JF, Kocher HM, Crnogorac-Jurcevic T, Scarpa A, Lemoine NR, Chelala C.

Genome Med. 2014 Dec 3;6(12):105. doi: 10.1186/s13073-014-0105-3. eCollection 2014.

22.

A vaccinia virus armed with interleukin-10 is a promising therapeutic agent for treatment of murine pancreatic cancer.

Chard LS, Maniati E, Wang P, Zhang Z, Gao D, Wang J, Cao F, Ahmed J, El Khouri M, Hughes J, Wang S, Li X, Denes B, Fodor I, Hagemann T, Lemoine NR, Wang Y.

Clin Cancer Res. 2015 Jan 15;21(2):405-16. doi: 10.1158/1078-0432.CCR-14-0464. Epub 2014 Nov 21.

23.

Nuclear translocation of FGFR1 and FGF2 in pancreatic stellate cells facilitates pancreatic cancer cell invasion.

Coleman SJ, Chioni AM, Ghallab M, Anderson RK, Lemoine NR, Kocher HM, Grose RP.

EMBO Mol Med. 2014 Apr;6(4):467-81. doi: 10.1002/emmm.201302698. Epub 2014 Feb 6.

24.

STAT1 interaction with E3-14.7K in monocytes affects the efficacy of oncolytic adenovirus.

Spurrell E, Gangeswaran R, Wang P, Cao F, Gao D, Feng B, Wold W, Tollefson A, Lemoine NR, Wang Y.

J Virol. 2014 Feb;88(4):2291-300. doi: 10.1128/JVI.02829-13. Epub 2013 Dec 11. Erratum in: J Virol. 2017 Sep 27;91(20):.

25.

Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging.

Allen MD, Luong P, Hudson C, Leyton J, Delage B, Ghazaly E, Cutts R, Yuan M, Syed N, Lo Nigro C, Lattanzio L, Chmielewska-Kassassir M, Tomlinson I, Roylance R, Whitaker HC, Warren AY, Neal D, Frezza C, Beltran L, Jones LJ, Chelala C, Wu BW, Bomalaski JS, Jackson RC, Lu YJ, Crook T, Lemoine NR, Mather S, Foster J, Sosabowski J, Avril N, Li CF, Szlosarek PW.

Cancer Res. 2014 Feb 1;74(3):896-907. doi: 10.1158/0008-5472.CAN-13-1702. Epub 2013 Nov 27.

26.

The pancreatic expression database: recent extensions and updates.

Dayem Ullah AZ, Cutts RJ, Ghetia M, Gadaleta E, Hahn SA, Crnogorac-Jurcevic T, Lemoine NR, Chelala C.

Nucleic Acids Res. 2014 Jan;42(Database issue):D944-9. doi: 10.1093/nar/gkt959. Epub 2013 Oct 25.

27.

Update on oncolytic viral therapy - targeting angiogenesis.

Tysome JR, Lemoine NR, Wang Y.

Onco Targets Ther. 2013 Jul 31;6:1031-40. doi: 10.2147/OTT.S46974. Print 2013.

28.

A practical guide for the functional annotation of genetic variations using SNPnexus.

Dayem Ullah AZ, Lemoine NR, Chelala C.

Brief Bioinform. 2013 Jul;14(4):437-47. doi: 10.1093/bib/bbt004. Epub 2013 Feb 8.

PMID:
23395730
29.

Molecular analysis of precursor lesions in familial pancreatic cancer.

Crnogorac-Jurcevic T, Chelala C, Barry S, Harada T, Bhakta V, Lattimore S, Jurcevic S, Bronner M, Lemoine NR, Brentnall TA.

PLoS One. 2013;8(1):e54830. doi: 10.1371/journal.pone.0054830. Epub 2013 Jan 23.

30.

Vascular endothelial growth factor A promotes vaccinia virus entry into host cells via activation of the Akt pathway.

Hiley CT, Chard LS, Gangeswaran R, Tysome JR, Briat A, Lemoine NR, Wang Y.

J Virol. 2013 Mar;87(5):2781-90. doi: 10.1128/JVI.00854-12. Epub 2012 Dec 26.

31.

A novel therapeutic regimen to eradicate established solid tumors with an effective induction of tumor-specific immunity.

Tysome JR, Li X, Wang S, Wang P, Gao D, Du P, Chen D, Gangeswaran R, Chard LS, Yuan M, Alusi G, Lemoine NR, Wang Y.

Clin Cancer Res. 2012 Dec 15;18(24):6679-89. doi: 10.1158/1078-0432.CCR-12-0979. Epub 2012 Oct 22.

32.

Adenovirus-mediated sensitization to the cytotoxic drugs docetaxel and mitoxantrone is dependent on regulatory domains in the E1ACR1 gene-region.

Miranda E, Maya Pineda H, Öberg D, Cherubini G, Garate Z, Lemoine NR, Halldén G.

PLoS One. 2012;7(10):e46617. doi: 10.1371/journal.pone.0046617. Epub 2012 Oct 3.

33.

S100P is a metastasis-associated gene that facilitates transendothelial migration of pancreatic cancer cells.

Barry S, Chelala C, Lines K, Sunamura M, Wang A, Marelli-Berg FM, Brennan C, Lemoine NR, Crnogorac-Jurcevic T.

Clin Exp Metastasis. 2013 Mar;30(3):251-64. doi: 10.1007/s10585-012-9532-y. Epub 2012 Sep 25.

PMID:
23007696
34.

Synergistic and Selective Cancer Cell Killing Mediated by the Oncolytic Adenoviral Mutant AdΔΔ and Dietary Phytochemicals in Prostate Cancer Models.

Adam V, Ekblad M, Sweeney K, Müller H, Busch KH, Johnsen CT, Kang NR, Lemoine NR, Halldén G.

Hum Gene Ther. 2012 Sep;23(9):1003-15. doi: 10.1089/hum.2012.046. Epub 2012 Aug 27.

35.

O-miner: an integrative platform for automated analysis and mining of -omics data.

Cutts RJ, Dayem Ullah AZ, Sangaralingam A, Gadaleta E, Lemoine NR, Chelala C.

Nucleic Acids Res. 2012 Jul;40(Web Server issue):W560-8. doi: 10.1093/nar/gks432. Epub 2012 May 17.

36.

SNPnexus: a web server for functional annotation of novel and publicly known genetic variants (2012 update).

Dayem Ullah AZ, Lemoine NR, Chelala C.

Nucleic Acids Res. 2012 Jul;40(Web Server issue):W65-70. doi: 10.1093/nar/gks364. Epub 2012 Apr 28.

37.

Systemic delivery of oncolytic viruses: hopes and hurdles.

Ferguson MS, Lemoine NR, Wang Y.

Adv Virol. 2012;2012:805629. doi: 10.1155/2012/805629. Epub 2012 Jan 31.

38.

Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11.

Wong HH, Jiang G, Gangeswaran R, Wang P, Wang J, Yuan M, Wang H, Bhakta V, Müller H, Lemoine NR, Wang Y.

Mol Ther. 2012 Feb;20(2):306-16. doi: 10.1038/mt.2011.242. Epub 2011 Nov 15.

39.

The oncolytic adenovirus AdΔΔ enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models.

Cherubini G, Kallin C, Mozetic A, Hammaren-Busch K, Müller H, Lemoine NR, Halldén G.

Gene Ther. 2011 Dec;18(12):1157-65. doi: 10.1038/gt.2011.141. Epub 2011 Oct 6.

PMID:
21975464
40.

AGR2 is a novel surface antigen that promotes the dissemination of pancreatic cancer cells through regulation of cathepsins B and D.

Dumartin L, Whiteman HJ, Weeks ME, Hariharan D, Dmitrovic B, Iacobuzio-Donahue CA, Brentnall TA, Bronner MP, Feakins RM, Timms JF, Brennan C, Lemoine NR, Crnogorac-Jurcevic T.

Cancer Res. 2011 Nov 15;71(22):7091-102. doi: 10.1158/0008-5472.CAN-11-1367. Epub 2011 Sep 26.

41.

An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine.

Bhattacharyya M, Francis J, Eddouadi A, Lemoine NR, Halldén G.

Cancer Gene Ther. 2011 Oct;18(10):734-43. doi: 10.1038/cgt.2011.45. Epub 2011 Aug 12.

PMID:
21836633
42.

A global insight into a cancer transcriptional space using pancreatic data: importance, findings and flaws.

Gadaleta E, Cutts RJ, Kelly GP, Crnogorac-Jurcevic T, Kocher HM, Lemoine NR, Chelala C.

Nucleic Acids Res. 2011 Oct;39(18):7900-7. doi: 10.1093/nar/gkr533. Epub 2011 Jun 30.

43.

Using BioMart as a framework to manage and query pancreatic cancer data.

Cutts RJ, Gadaleta E, Lemoine NR, Chelala C.

Database (Oxford). 2011 Jun 11;2011:bar024. doi: 10.1093/database/bar024. Print 2011.

44.

Lister vaccine strain of vaccinia virus armed with the endostatin-angiostatin fusion gene: an oncolytic virus superior to dl1520 (ONYX-015) for human head and neck cancer.

Tysome JR, Wang P, Alusi G, Briat A, Gangeswaran R, Wang J, Bhakta V, Fodor I, Lemoine NR, Wang Y.

Hum Gene Ther. 2011 Sep;22(9):1101-8. doi: 10.1089/hum.2010.172. Epub 2011 Apr 18.

PMID:
21361787
45.

The Pancreatic Expression database: 2011 update.

Cutts RJ, Gadaleta E, Hahn SA, Crnogorac-Jurcevic T, Lemoine NR, Chelala C.

Nucleic Acids Res. 2011 Jan;39(Database issue):D1023-8. doi: 10.1093/nar/gkq937. Epub 2010 Oct 18.

46.

PRSS3 promotes tumour growth and metastasis of human pancreatic cancer.

Jiang G, Cao F, Ren G, Gao D, Bhakta V, Zhang Y, Cao H, Dong Z, Zang W, Zhang S, Wong HH, Hiley C, Crnogorac-Jurcevic T, Lemoine NR, Wang Y.

Gut. 2010 Nov;59(11):1535-44. doi: 10.1136/gut.2009.200105.

PMID:
20947888
47.

Novel therapies for pancreatic cancer: setbacks and progress.

Wong HH, Lemoine NR.

Future Oncol. 2010 Jul;6(7):1061-4. doi: 10.2217/fon.10.70. No abstract available.

48.

Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.

Wong HH, Lemoine NR, Wang Y.

Viruses. 2010 Jan;2(1):78-106.

49.

Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis.

Mao X, Yu Y, Boyd LK, Ren G, Lin D, Chaplin T, Kudahetti SC, Stankiewicz E, Xue L, Beltran L, Gupta M, Oliver RT, Lemoine NR, Berney DM, Young BD, Lu YJ.

Cancer Res. 2010 Jul 1;70(13):5207-12. doi: 10.1158/0008-5472.CAN-09-4074. Epub 2010 Jun 1.

50.

Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts.

Radhakrishnan S, Miranda E, Ekblad M, Holford A, Pizarro MT, Lemoine NR, Halldén G.

Hum Gene Ther. 2010 Oct;21(10):1311-25. doi: 10.1089/hum.2010.019.

PMID:
20497039

Supplemental Content

Loading ...
Support Center